Login / Signup

Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY.

Amelia C A GreenHelen J CurtisRose HigginsLinda NabViyaasan MahalingasivamRebecca M SmithAmir MehrkarPeter InglesbyHenry DrysdaleNicholas J DeVitoRichard CrokerChristopher T RentschKrishnan BhaskaranJohn TazareBang ZhengColm D AndrewsSebastian C J BaconSimon DavyIain DillinghamDavid EvansLouis FisherGeorge HickmanLisa E M HopcroftWilliam J HulmeJon MasseyOrla MacDonaldJessica MorleyCaroline E MortonRobin Y ParkAlex J WalkerTom WardMilan WiedemannChristopher BatesJonathan CockburnJohn ParryFrank HesterSam HarperIan J DouglasStephen J W EvansAlex J WalkerLaurie A TomlinsonBrian Mackenna
Published in: BMJ medicine (2023)
Using the OpenSAFELY platform, we were able to identify patients with covid-19 at high risk of severe outcomes who were potentially eligible to receive treatment and assess the coverage of these new treatments among these patients. In the context of a rapid deployment of a new service, the NHS analytical code used to determine eligibility could have been over-inclusive and some of the eligibility criteria not fully captured in healthcare data. However targeted activity might be needed to resolve apparent lower treatment coverage observed among certain groups, in particular (at present): different NHS regions, ethnic groups, people aged ≥80 years, those living in socioeconomically deprived areas, and care home residents.
Keyphrases